+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Beta-Nicotinamide Mononucleotide Market - Global Forecast 2025-2030- Product Image
Beta-Nicotinamide Mononucleotide Market - Global Forecast 2025-2030- Product Image
Sale

Beta-Nicotinamide Mononucleotide Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6078913
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Unlocking the Potential of Beta-Nicotinamide Mononucleotide to Revolutionize Cellular Health and Redefine Therapeutic Strategies Worldwide

Beta-nicotinamide mononucleotide has rapidly emerged as a molecule of high interest within scientific, pharmaceutical, and nutraceutical communities, owing to its central role in supporting NAD+ biosynthesis and cellular energy functions. Its unique position at the intersection of metabolism and longevity research has catalyzed exploratory studies aimed at clarifying mechanisms of action, safety profiles, and potential therapeutic applications. As a result, established research institutions and innovative startups alike are dedicating resources to elucidate its benefits across health, beauty, and animal performance sectors.

In this introduction, the evolution of beta-nicotinamide mononucleotide from a biochemical curiosity to a commercial ingredient is traced alongside key milestones in synthesis technologies, preclinical and clinical investigations, and early market adoption strategies. By considering current research trends, regulatory landscapes, and emerging application areas, this section lays the foundation for understanding the transformative potential of this compound and sets the stage for deeper analysis in subsequent sections.

Unprecedented Shifts in the Global Beta-Nicotinamide Mononucleotide Landscape Driven by Technological Breakthroughs and Innovation Pathways

The marketplace for beta-nicotinamide mononucleotide is undergoing unprecedented change driven by breakthroughs in enzymatic biosynthesis and advanced purification methods. Innovative production pathways that leverage microbial fermentation and enzyme-catalyzed conversion have significantly reduced impurity levels and improved yield consistency. Concurrently, breakthroughs in formulation science are enhancing bioavailability, enabling novel delivery systems that cater to diverse end-user requirements, from dermatological serums to injectable therapies.

Alongside technological innovation, collaborative efforts among research institutions, contract manufacturers, and ingredient formulators are reshaping traditional development timelines. Strategic partnerships that integrate academic expertise with private-sector agility are accelerating proof-of-concept studies and expedited regulatory submissions. In tandem, the integration of digital analytics and predictive modeling tools is providing stakeholders with unprecedented clarity on process optimization, risk mitigation, and scale-up feasibility, ultimately fostering an environment of rapid iteration and continuous improvement.

Assessing the Cumulative Impact of 2025 United States Tariffs on Beta-Nicotinamide Mononucleotide Supply Chains and Market Accessibility

The imposition of revised United States tariff schedules in 2025 has introduced notable complexities within global supply chains for beta-nicotinamide mononucleotide. Manufacturers reliant on imported raw precursors have encountered increased landed costs, prompting a recalibration of procurement strategies and a reevaluation of sourcing alternatives. In response to elevated duties, several stakeholders have initiated nearshoring discussions to mitigate exposure and secure alternative production routes closer to key end markets.

These tariff adjustments have also driven greater collaboration among North American manufacturers and research partners to localize upstream processes. By investing in domestic fermentation facilities and expanding in-house synthesis capabilities, some players are seeking to retain competitive pricing while minimizing logistical risks. At the same time, downstream formulators are adopting dynamic pricing models, leveraging long-term supplier contracts and hedging mechanisms to preserve margin stability and safeguard customer relationships.

Delving into Application, Product Form, Distribution Channel, Source, Purity Grade, and Manufacturing Technology Segmentation to Unveil Market Nuances

Evaluation of application segments reveals that beta-nicotinamide mononucleotide’s integration into animal nutrition encompasses both companion animals and livestock, where it is investigated for its potential to support vitality and stress resilience. In the cosmetics domain, anti-aging treatments, moisturizing formulations, and skin lightening preparations are progressively incorporating this compound, reflecting its mechanistic ties to cellular repair and antioxidant activity. Dietary supplements have converged on effervescent tablets, gummy formulations, and traditional oral capsules as preferred delivery modes, each tailored to optimize user compliance and sensory experience. Within the functional beverage sector, energy drinks, juices, and soft drinks are exploring synergistic blends that enhance both taste and perceived efficacy. Pharmaceutical research pipelines are concurrently assessing anti-aging drug candidates, metabolic disorder therapies, and neuroprotective agents, underscoring the molecule’s versatility.

From a product form perspective, hard capsules, softgel capsules, and tablets remain foundational in solid dosage design, whereas drops and syrup formats cater to consumer preferences for liquid administration. Bulk powders and sachet options offer scalable advantages for industrial users and personalized dosing. Distribution channels span clinical environments in hospitals, niche health outlets, online platforms, pharmacy networks, specialized retailers, and large-format supermarkets and hypermarkets, each presenting unique regulatory, logistical, and promotional nuances. Source differentiation between biochemical synthesis and fermentation pathways underpins quality and cost considerations, while distinct purity grades-ranging from below ninety-five percent, through ninety-five to ninety-eight percent, to above ninety-eight percent-drive formulation choices and compliance requirements. Manufacturing technologies further diverge into biosynthetic methods that capitalize on biological catalysts and chemical synthesis routes that deliver precision at scale.

Analyzing Distinct Regional Dynamics Across Americas, Europe Middle East Africa, and Asia Pacific to Highlight Growth Drivers and Regional Demand Patterns

Geographically, the Americas region has been characterized by robust consumer demand for premium wellness ingredients and a supportive regulatory framework for nutraceutical innovation. High levels of private investment in clinical research and manufacturing infrastructure have positioned North America as both a major consumer and a strategic export hub for intermediates and finished formulations.

In contrast, Europe, the Middle East, and Africa exhibit diverse regulatory paradigms and market maturity. Western European markets prioritize stringent quality standards and claim substantiation, while emerging markets in the Middle East and parts of Africa demonstrate growing interest in domestic production and import substitution strategies. Cross-regional partnerships and knowledge exchange initiatives are increasingly bridging gaps in technical expertise and regulatory alignment.

Within the Asia-Pacific zone, rapid industrial expansion, government incentives for biotechnology ventures, and a burgeoning middle-class consumer base are fueling accelerated adoption. Local manufacturers are scaling fermentation and chemical synthesis operations to feed both regional and export demand, with an emphasis on cost optimization and supply chain resilience. This region’s dynamic ecosystem is expected to continue shaping global trade flows and competitive benchmarks.

Mapping Competitive Landscapes by Profiling Leading Beta-Nicotinamide Mononucleotide Manufacturers and Their Strategic Imperatives for Market Leadership

The competitive landscape for beta-nicotinamide mononucleotide is defined by entities that blend deep biochemical expertise with scalable production capabilities. Leading ingredient innovators such as ChromaDex and Elysium Health have staked positions through proprietary extraction and stabilization technologies, while specialty chemical suppliers like BASF and Lonza leverage extensive regulatory experience to serve pharmaceutical and nutraceutical clients alike. Emerging players, including TA Sciences and AliveByNature, are distinguishing themselves through collaborations with academic research centers and targeted investments in process intensification.

Strategic imperatives vary across these companies, with some prioritizing vertical integration to manage cost structures and raw material security, and others focusing on co-development partnerships that expedite market entry. Intellectual property portfolios centered on novel catalysts and formulation patents serve as critical competitive barriers, while continuous R&D commitments drive next-generation delivery solutions. As competition intensifies, alliances between ingredient suppliers, contract manufacturers, and brand owners will likely shape collaborative models aimed at reducing time-to-market and enhancing product differentiation.

Driving Strategic Excellence with Actionable Recommendations for Industry Leaders to Capitalize on Beta-Nicotinamide Mononucleotide Innovations and Emerging Opportunities

Industry leaders can elevate their market positioning by maximizing strategic investments in both upstream process innovation and downstream application development. Establishing joint ventures with fermentation technology experts or enzyme engineering firms will bolster production flexibility and cost competitiveness, ensuring rapid responsiveness to tariff fluctuations and raw material availability.

Simultaneously, prioritizing partnerships with specialized contract research organizations and formulation houses accelerates validation pathways for novel applications in cosmetics, functional foods, and therapeutic categories. Emphasizing the development of ultra-high purity grades and advanced delivery systems will address premium segment demands and facilitate entry into regulated pharmaceutical markets. Finally, deploying comprehensive supply chain audits and risk management frameworks will enhance resilience against geopolitical shifts, while digital traceability solutions reinforce quality assurance and regulatory compliance across global operations.

Unveiling the Rigorous Research Methodology Employed to Analyze Beta-Nicotinamide Mononucleotide Market Dynamics, Data Sources, and Analytical Frameworks

The research methodology underpinning this analysis combined in-depth expert interviews, rigorous review of scientific literature and patent filings, and systematic evaluation of regulatory documents from key jurisdictions. Primary consultations with senior executives, technical directors, and regulatory affairs specialists provided qualitative insights into strategic priorities, perceived risks, and investment trajectories.

Secondary data sources included peer-reviewed journals, conference proceedings, corporate white papers, and publicly available financial disclosures. Quantitative datasets were triangulated through cross-validation protocols, ensuring consistency between import-export statistics, production capacity estimates, and patent activity trends. Analytical frameworks encompassed SWOT analyses, scenario planning for tariff impacts, and value-chain mapping, each calibrated to highlight the interdependencies between innovation, regulation, and market access.

Summarizing Key Findings and Future Outlook to Provide a Strategic Conclusion on Beta-Nicotinamide Mononucleotide Market Trajectories and Their Implications

This comprehensive examination underscores the convergence of technological advancements, regulatory evolution, and shifting consumer preferences that are collectively shaping the beta-nicotinamide mononucleotide landscape. From segmentation nuances in applications and product forms to regional disparities and competitive strategies, the intricate interplay of these factors determines market trajectories and growth potential.

Looking ahead, the ability of stakeholders to integrate robust synthesis technologies, uphold stringent quality standards, and forge strategic collaborations will dictate success. Remaining cognizant of geopolitical influences such as tariff policies, while proactively exploring diversification pathways, will be critical. In synthesis, a balanced approach that marries innovation with operational resilience is paramount for capitalizing on the expanding opportunities within this dynamic sector.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Application
    • Animal Feed
      • Companion Animals
      • Livestock
    • Cosmetics
      • Anti-Aging
      • Moisturizers
      • Skin Lightening
    • Dietary Supplements
      • Effervescent Tablets
      • Gummies
      • Oral Supplements
    • Functional Beverages
      • Energy Drinks
      • Juices
      • Soft Drinks
    • Pharmaceuticals
      • Anti-Aging Drugs
      • Metabolic Disorder Drugs
      • Neuroprotective Drugs
  • Product Form
    • Capsules Tablets
      • Hard Capsules
      • Softgel Capsules
      • Tablets
    • Liquids
      • Drops
      • Syrups
    • Powders
      • Bulk Powders
      • Sachet Powders
  • Distribution Channel
    • Hospitals
    • Nutrition Health Stores
    • Online Retail
    • Pharmacies Drugstores
    • Specialty Stores
    • Supermarkets Hypermarkets
  • Source
    • Biochemical Synthesis
    • Fermentation
  • Purity Grade
    • 95 To 98
    • 98 And Above
    • Below 95
  • Manufacturing Technology
    • Biosynthesis
    • Chemical Synthesis
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Elevant Inc.
  • Compound Solutions, LLC
  • GeneHarbor Biotech (Shanghai) Co., Ltd
  • Jiangsu Wuzhong Pharmaceutical Co., Ltd
  • Hunan Nutramax Inc.
  • Nantong Eson Biotechnology Co., Ltd
  • Bontoux Laboratories, Ltd.
  • Shandong Doteer Biotechnology Co., Ltd
  • Beijing Beasky Biotechnology Co., Ltd

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Growing adoption of sustained-release beta-nicotinamide mononucleotide formulations for enhanced bioavailability and compliance
5.2. Integration of NMN with peptide complexes in antiaging cosmeceuticals to target skin elasticity at the dermal layer
5.3. Expansion of direct-to-consumer subscription services for daily NMN supplements driven by personalized health trends
5.4. Surge in investments for enzymatic biosynthesis technologies to lower cost of NMN production and improve purity
5.5. Regulatory harmonization efforts in EU and US to establish quality standards for NMN ingredient labeling and safety
5.6. Collaborative research between biotech startups and academic labs investigating NMN’s role in neuroprotection for cognitive health
5.7. Emergence of nanocarrier-based oral NMN delivery systems to overcome gastrointestinal degradation and enhance absorption
5.8. Rising demand for vegan and sustainably sourced NMN ingredients in response to environmental and ethical consumer preferences
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Beta-Nicotinamide Mononucleotide Market, by Application
8.1. Introduction
8.2. Animal Feed
8.2.1. Companion Animals
8.2.2. Livestock
8.3. Cosmetics
8.3.1. Anti-Aging
8.3.2. Moisturizers
8.3.3. Skin Lightening
8.4. Dietary Supplements
8.4.1. Effervescent Tablets
8.4.2. Gummies
8.4.3. Oral Supplements
8.5. Functional Beverages
8.5.1. Energy Drinks
8.5.2. Juices
8.5.3. Soft Drinks
8.6. Pharmaceuticals
8.6.1. Anti-Aging Drugs
8.6.2. Metabolic Disorder Drugs
8.6.3. Neuroprotective Drugs
9. Beta-Nicotinamide Mononucleotide Market, by Product Form
9.1. Introduction
9.2. Capsules Tablets
9.2.1. Hard Capsules
9.2.2. Softgel Capsules
9.2.3. Tablets
9.3. Liquids
9.3.1. Drops
9.3.2. Syrups
9.4. Powders
9.4.1. Bulk Powders
9.4.2. Sachet Powders
10. Beta-Nicotinamide Mononucleotide Market, by Distribution Channel
10.1. Introduction
10.2. Hospitals
10.3. Nutrition Health Stores
10.4. Online Retail
10.5. Pharmacies Drugstores
10.6. Specialty Stores
10.7. Supermarkets Hypermarkets
11. Beta-Nicotinamide Mononucleotide Market, by Source
11.1. Introduction
11.2. Biochemical Synthesis
11.3. Fermentation
12. Beta-Nicotinamide Mononucleotide Market, by Purity Grade
12.1. Introduction
12.2. 95 To 98
12.3. 98 And Above
12.4. Below 95
13. Beta-Nicotinamide Mononucleotide Market, by Manufacturing Technology
13.1. Introduction
13.2. Biosynthesis
13.3. Chemical Synthesis
14. Americas Beta-Nicotinamide Mononucleotide Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Beta-Nicotinamide Mononucleotide Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Beta-Nicotinamide Mononucleotide Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Elevant Inc.
17.3.2. Compound Solutions, LLC
17.3.3. GeneHarbor Biotech (Shanghai) Co., Ltd
17.3.4. Jiangsu Wuzhong Pharmaceutical Co., Ltd
17.3.5. Hunan Nutramax Inc.
17.3.6. Nantong Eson Biotechnology Co., Ltd
17.3.7. Bontoux Laboratories, Ltd.
17.3.8. Shandong Doteer Biotechnology Co., Ltd
17.3.9. Beijing Beasky Biotechnology Co., Ltd
18. Research AI19. Research Statistics20. Research Contacts21. Research Articles22. Appendix
List of Figures
FIGURE 1. BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PRODUCT FORM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PRODUCT FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PURITY GRADE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PURITY GRADE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET: RESEARCHAI
FIGURE 28. BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET: RESEARCHSTATISTICS
FIGURE 29. BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET: RESEARCHCONTACTS
FIGURE 30. BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANIMAL FEED, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANIMAL FEED, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANIMAL FEED, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANIMAL FEED, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COSMETICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COSMETICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANTI-AGING, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANTI-AGING, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY MOISTURIZERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY MOISTURIZERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SKIN LIGHTENING, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SKIN LIGHTENING, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COSMETICS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COSMETICS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY EFFERVESCENT TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY EFFERVESCENT TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY GUMMIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY GUMMIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ORAL SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ORAL SUPPLEMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DIETARY SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY FUNCTIONAL BEVERAGES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY FUNCTIONAL BEVERAGES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ENERGY DRINKS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ENERGY DRINKS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY JUICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY JUICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOFT DRINKS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOFT DRINKS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY FUNCTIONAL BEVERAGES, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY FUNCTIONAL BEVERAGES, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANTI-AGING DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANTI-AGING DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY METABOLIC DISORDER DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY METABOLIC DISORDER DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY NEUROPROTECTIVE DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY NEUROPROTECTIVE DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY CAPSULES TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY CAPSULES TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY HARD CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY HARD CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOFTGEL CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOFTGEL CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY CAPSULES TABLETS, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY CAPSULES TABLETS, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY LIQUIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DROPS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DROPS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SYRUPS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SYRUPS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY LIQUIDS, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY LIQUIDS, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY POWDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY BULK POWDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY BULK POWDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SACHET POWDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SACHET POWDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY POWDERS, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY POWDERS, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY NUTRITION HEALTH STORES, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY NUTRITION HEALTH STORES, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PHARMACIES DRUGSTORES, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PHARMACIES DRUGSTORES, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SPECIALTY STORES, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SPECIALTY STORES, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SUPERMARKETS HYPERMARKETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SUPERMARKETS HYPERMARKETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY BIOCHEMICAL SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY BIOCHEMICAL SYNTHESIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY FERMENTATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY FERMENTATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PURITY GRADE, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PURITY GRADE, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY 95 TO 98, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY 95 TO 98, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY 98 AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY 98 AND ABOVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY BELOW 95, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY BELOW 95, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY BIOSYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY BIOSYNTHESIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANIMAL FEED, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANIMAL FEED, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COSMETICS, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COSMETICS, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DIETARY SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY FUNCTIONAL BEVERAGES, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY FUNCTIONAL BEVERAGES, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY CAPSULES TABLETS, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY CAPSULES TABLETS, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY LIQUIDS, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY LIQUIDS, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY POWDERS, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY POWDERS, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PURITY GRADE, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PURITY GRADE, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANIMAL FEED, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANIMAL FEED, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COSMETICS, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COSMETICS, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DIETARY SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY FUNCTIONAL BEVERAGES, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY FUNCTIONAL BEVERAGES, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY CAPSULES TABLETS, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY CAPSULES TABLETS, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY LIQUIDS, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY LIQUIDS, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY POWDERS, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY POWDERS, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PURITY GRADE, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PURITY GRADE, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 181. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 182. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 183. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANIMAL FEED, 2018-2024 (USD MILLION)
TABLE 184. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANIMAL FEED, 2025-2030 (USD MILLION)
TABLE 185. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COSMETICS, 2018-2024 (USD MILLION)
TABLE 186. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COSMETICS, 2025-2030 (USD MILLION)
TABLE 187. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 188. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DIETARY SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 189. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY FUNCTIONAL BEVERAGES, 2018-2024 (USD MILLION)
TABLE 190. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY FUNCTIONAL BEVERAGES, 2025-2030 (USD MILLION)
TABLE 191. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 192. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 193. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 194. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 195. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY CAPSULES TABLETS, 2018-2024 (USD MILLION)
TABLE 196. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY CAPSULES TABLETS, 2025-2030 (USD MILLION)
TABLE 197. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY LIQUIDS, 2018-2024 (USD MILLION)
TABLE 198. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY LIQUIDS, 2025-2030 (USD MILLION)
TABLE 199. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY POWDERS, 2018-2024 (USD MILLION)
TABLE 200. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY POWDERS, 2025-2030 (USD MILLION)
TABLE 201. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 204. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 205. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PURITY GRADE, 2018-2024 (USD MILLION)
TABLE 206. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PURITY GRADE, 2025-2030 (USD MILLION)
TABLE 207. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 208. CANADA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 209. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 210. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 211. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANIMAL FEED, 2018-2024 (USD MILLION)
TABLE 212. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANIMAL FEED, 2025-2030 (USD MILLION)
TABLE 213. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COSMETICS, 2018-2024 (USD MILLION)
TABLE 214. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COSMETICS, 2025-2030 (USD MILLION)
TABLE 215. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 216. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DIETARY SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 217. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY FUNCTIONAL BEVERAGES, 2018-2024 (USD MILLION)
TABLE 218. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY FUNCTIONAL BEVERAGES, 2025-2030 (USD MILLION)
TABLE 219. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 220. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 221. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 222. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 223. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY CAPSULES TABLETS, 2018-2024 (USD MILLION)
TABLE 224. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY CAPSULES TABLETS, 2025-2030 (USD MILLION)
TABLE 225. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY LIQUIDS, 2018-2024 (USD MILLION)
TABLE 226. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY LIQUIDS, 2025-2030 (USD MILLION)
TABLE 227. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY POWDERS, 2018-2024 (USD MILLION)
TABLE 228. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY POWDERS, 2025-2030 (USD MILLION)
TABLE 229. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 232. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 233. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PURITY GRADE, 2018-2024 (USD MILLION)
TABLE 234. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PURITY GRADE, 2025-2030 (USD MILLION)
TABLE 235. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 236. MEXICO BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 237. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 238. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 239. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANIMAL FEED, 2018-2024 (USD MILLION)
TABLE 240. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANIMAL FEED, 2025-2030 (USD MILLION)
TABLE 241. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COSMETICS, 2018-2024 (USD MILLION)
TABLE 242. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COSMETICS, 2025-2030 (USD MILLION)
TABLE 243. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 244. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DIETARY SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY FUNCTIONAL BEVERAGES, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY FUNCTIONAL BEVERAGES, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY CAPSULES TABLETS, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY CAPSULES TABLETS, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY LIQUIDS, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY LIQUIDS, 2025-2030 (USD MILLION)
TABLE 255. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY POWDERS, 2018-2024 (USD MILLION)
TABLE 256. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY POWDERS, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 261. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PURITY GRADE, 2018-2024 (USD MILLION)
TABLE 262. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PURITY GRADE, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 265. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 266. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 267. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANIMAL FEED, 2018-2024 (USD MILLION)
TABLE 268. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANIMAL FEED, 2025-2030 (USD MILLION)
TABLE 269. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COSMETICS, 2018-2024 (USD MILLION)
TABLE 270. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COSMETICS, 2025-2030 (USD MILLION)
TABLE 271. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 272. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DIETARY SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 273. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY FUNCTIONAL BEVERAGES, 2018-2024 (USD MILLION)
TABLE 274. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY FUNCTIONAL BEVERAGES, 2025-2030 (USD MILLION)
TABLE 275. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 276. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 277. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 278. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 279. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY CAPSULES TABLETS, 2018-2024 (USD MILLION)
TABLE 280. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY CAPSULES TABLETS, 2025-2030 (USD MILLION)
TABLE 281. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY LIQUIDS, 2018-2024 (USD MILLION)
TABLE 282. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY LIQUIDS, 2025-2030 (USD MILLION)
TABLE 283. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY POWDERS, 2018-2024 (USD MILLION)
TABLE 284. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY POWDERS, 2025-2030 (USD MILLION)
TABLE 285. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 288. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 289. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PURITY GRADE, 2018-2024 (USD MILLION)
TABLE 290. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY PURITY GRADE, 2025-2030 (USD MILLION)
TABLE 291. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 292. ARGENTINA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANIMAL FEED, 2018-2024 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY ANIMAL FEED, 2025-2030 (USD MILLION)
TABLE 297. EUROPE, MIDDLE EAST & AFRICA BETA-NICOTINAMIDE MONONUCLEOTIDE MARKET SIZE, BY COSMETICS, 2018-2024 (USD MILLION)
TABLE 298. EUROPE, MIDDLE EAST & AF

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Beta-Nicotinamide Mononucleotide market report include:
  • Elevant Inc.
  • Compound Solutions, LLC
  • GeneHarbor Biotech (Shanghai) Co., Ltd
  • Jiangsu Wuzhong Pharmaceutical Co., Ltd
  • Hunan Nutramax Inc.
  • Nantong Eson Biotechnology Co., Ltd
  • Bontoux Laboratories, Ltd.
  • Shandong Doteer Biotechnology Co., Ltd
  • Beijing Beasky Biotechnology Co., Ltd

Related Topics

Related Reports

Cosmetic Grade Nicotinamide Mononucleotide Market - Global Forecast 2025-2030 - Product Image

Cosmetic Grade Nicotinamide Mononucleotide Market - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Nicotinamide Mononucleotide (NMN) Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Nicotinamide Mononucleotide (NMN) Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
a-Nicotinamide Mononucleotide (CAS 7298-94-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

a-Nicotinamide Mononucleotide (CAS 7298-94-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
ß-Nicotinamide Mononucleotide (CAS 1094-61-7) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

ß-Nicotinamide Mononucleotide (CAS 1094-61-7) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 51 Pages
  • Global
From
Nicotinamide Adenine Dinucleotide - Global Strategic Business Report - Product Image

Nicotinamide Adenine Dinucleotide - Global Strategic Business Report

  • Report
  • 276 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.